Corcept's Q4 Earnings and Revenues Fall Short of Estimates

Key Takeaways CORT posted Q4 EPS of 20 cents, missing estimates. Revenues rose 11% Y/Y to $202.1M in Q4 2025.CORT expects 2026 revenues of $900M-$1B. FDA decision on relacorilant in ovarian cancer is due in July 2026.Corcept received the FDA's CRL for relacorilant in Cushing's syndrome and is engaging in the next steps.Corcept Therapeutics (CORT) reported fourth-quarter 2025 earnings of 20 cents per share, which missed the Zacks Consensus Estimate of 27 cents. The company had reported earnings of 26 cents p ...